FOAMIX - DAILY CHART
Foamix Pharmaceuticals its gathering the attention of investors around the reporting of worse than expected earnings with an EPS of -0.35, representing -2.94% of the forecasted. The company also announced the Merging with Menlo Therapeutics (MNLO) focused on the development and commercialization of therapeutics for dermatologic indications. These news can imply an increase in volatility on the asset and further investors' especulation.
Feragatname
Bilgiler ve yayınlar, TradingView tarafından sağlanan veya onaylanan finansal, yatırım, işlem veya diğer türden tavsiye veya tavsiyeler anlamına gelmez ve teşkil etmez. Kullanım Şartları'nda daha fazlasını okuyun.